P/E ratio for Merrimack Pharmaceuticals (MACK)
P/E ratio as of April 2024 (TTM): -134
According to Merrimack Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -133.909. At the end of 2022 the company had a P/E ratio of -104.
P/E ratio history for Merrimack Pharmaceuticals from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -104 | 379.61% |
| 2021 | -21.7 | -24.33% |
| 2020 | -28.7 | 1084.79% |
| 2019 | -2.42 | 140.95% |
| 2018 | -1.01 | -542.8% |
| 2017 | 0.2271 | -108.65% |
| 2016 | -2.62 | -44.26% |
| 2015 | -4.71 | -57.63% |
| 2014 | -11.1 | 249.81% |
| 2013 | -3.18 | 90.29% |
| 2012 | -1.67 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | 15.4 | -111.54% | 🇫🇷 France |
 Geron GERN | -11.1 | -91.68% | 🇺🇸 USA |
 Clovis Oncology CLVS | -0.0430 | -99.97% | 🇺🇸 USA |
 AVEO Oncology
AVEO | -17.9 | -86.66% | 🇺🇸 USA |
 Eterna Therapeutics ERNA | -0.3174 | -99.76% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.